Literature DB >> 7580836

Impairment of circulating lactoferrin in HIV-1 infection.

M C Defer1, B Dugas, O Picard, C Damais.   

Abstract

Levels of plasma lactoferrin are decreased in HIV-1-infected patients in relation to the progression of the disease. Plasma lactoferrin concentrations were determined using a specific and sensitive enzyme immunoassay. 97 plasma were studied (22 asymptomatic, 45 symptomatic patients compared to 30 healthy controls) and the results showed a highly significant decrease (p < 0.001) of the level of lactoferrin in HIV-1-infected patients (respectively 2.79 +/- 1.2 and 0.68 +/- 0.22 micrograms/ml) compared to controls (4.37 +/- 0.83 micrograms/ml). Since it is well established that plasma lactoferrin level could be influenced by the number of neutrophils, the experiments were reproduced in neutropenic patients who represent 10% of recruitment (6 among 45 symptomatic patients). The plasma from neutropenic symptomatic patients (neutrophils < or = 1,300/mm3) showed their mean lactoferrin level at 0.36 micrograms/ml still far above the normal values. In view of the different reported biological effects of lactoferrin that are of great importance in the non-specific defences, the real biological place of the lack of such a molecule could be one important component of the multifactorial nature of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7580836

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  8 in total

1.  Hepatitis C virus envelope proteins bind lactoferrin.

Authors:  M Yi; S Kaneko; D Y Yu; S Murakami
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  A human milk factor susceptible to cathepsin D inhibitors enhances human immunodeficiency virus type 1 infectivity and allows virus entry into a mammary epithelial cell line.

Authors:  K El Messaoudi; L F Thiry; C Liesnard; N Van Tieghem; A Bollen; N Moguilevsky
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Action of deferoxamine against Pneumocystis carinii.

Authors:  A B Clarkson; D Turkel-Parrella; J H Williams; L C Chen; T Gordon; S Merali
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

4.  Modulation of HIV Binding to Epithelial Cells and HIV Transfer from Immature Dendritic Cells to CD4 T Lymphocytes by Human Lactoferrin and its Major Exposed LF-33 Peptide.

Authors:  Laetitia Carthagena; Pierre Becquart; Hakim Hocini; Michel D Kazatchkine; Hicham Bouhlal; Laurent Belec
Journal:  Open Virol J       Date:  2011-04-15

5.  Lactotransferrin gene functional polymorphisms do not influence susceptibility to human immunodeficiency virus-1 mother-to-child transmission in different ethnic groups.

Authors:  Luisa Zupin; Vania Polesello; Antonio Victor Campos Coelho; Michele Boniotto; Luiz Claudio Arraes; Ludovica Segat; Sergio Crovella
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-04-01       Impact factor: 2.743

6.  Immune Suppression by Myeloid Cells in HIV Infection: New Targets for Immunotherapy.

Authors:  Vikram Mehraj; Mohammad-Ali Jenabian; Kishanda Vyboh; Jean-Pierre Routy
Journal:  Open AIDS J       Date:  2014-12-29

7.  Dose-response trial of lactoferrin in patients with chronic hepatitis C.

Authors:  Shuichi Okada; Katsuaki Tanaka; Tosiya Sato; Hideki Ueno; Satoru Saito; Takuji Okusaka; Keiko Sato; Seiichiro Yamamoto; Tadao Kakizoe
Journal:  Jpn J Cancer Res       Date:  2002-09

Review 8.  Human Antimicrobial Peptides as Therapeutics for Viral Infections.

Authors:  Aslaa Ahmed; Gavriella Siman-Tov; Grant Hall; Nishank Bhalla; Aarthi Narayanan
Journal:  Viruses       Date:  2019-08-01       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.